盈康生命卸下14.58亿“历史包袱”，轻装上阵激活发展新动能

Group 1 - The company plans to use a total of 1.458 billion yuan from its surplus and capital reserves to cover accumulated losses, primarily due to asset impairment from acquisitions made before Haier's takeover [1] - The losses are attributed to prior years' asset impairment losses and investment losses from the transfer of subsidiary equity, mainly related to assets acquired before Haier's involvement [1] - This financial restructuring is a common practice for listed companies to optimize their financial structure and is in line with the new Company Law and relevant guidelines from the Ministry of Finance [1] Group 2 - The financial adjustment is not a reactive measure due to operational pressure; the company has achieved steady profitability, with a net profit of 100 million yuan in 2023, a year-on-year increase of 116.9% [2] - Projected net profit for 2024 is 115 million yuan, reflecting a growth of 14.92%, and the company started 2025 with a strong first quarter net profit of 29.99 million yuan [2] - The company is entering a new development phase, driven by the dual engines of medical services and high-end medical devices, enhanced by "medical + AI" technology [2]